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soft tissue infections. Abscesses are a frequent manifestation of S. aureus skin and soft tissue infections
and are formed, in part, to contain the nidus of infection. Polymorphonuclear leukocytes (neutrophils)
are the primary cellular host defense against S. aureus infections and a major component of S. aureus
abscesses. These host cells contain and produce many antimicrobial agents that are effective at killing
bacteria, but can also cause non-speciﬁc damage to host tissues and contribute to the formation of
abscesses. By comparison, S. aureus produces several molecules that also contribute to the formation of
abscesses. Such molecules include those that recruit neutrophils, cause host cell lysis, and are involved
in the formation of the ﬁbrin capsule surrounding the abscess. Herein, we review our current knowledge
of the mechanisms and processes underlying the formation of S. aureus abscesses, including the
involvement of polymorphonuclear leukocytes, and provide a brief overview of therapeutic approaches.
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This article is part of a review series on infectious disease.Staphylococcus aureus is a widespread commensal bacte-
rium and pathogen. Approximately 50% to 60% of in-
dividuals are intermittently or permanently colonized with
S. aureus and, thus, there is relatively high potential for
infections.1,2 Indeed, S. aureus is among the most promi-
nent causes of bacterial infections in the United States and
other industrialized countries.3,4 For example, S. aureus
was the most frequently recovered bacterium from in-
patients among 300 clinical microbiology laboratories in the
United States from 1998 to 2005.5 Staphylococcus aureus
ranked second (after Escherichia coli) among bacterial
isolates recovered from bacteremias in Europe in 2008, and
the prevalence of S. aureus bacteremias increased from
2002 to 2008.4 Recently, S. aureus has been reported to be
second only to Clostridium difﬁcile as a cause of health
careeassociated infections in the United States.6
In addition to its high prevalence, S. aureus is well known
for its ability to acquire resistance to antibiotics. Notably,
antibiotic resistance in S. aureus has occurred in epidemic
waves.7 Penicillin-resistant S. aureus emerged in the late
1940s, and by the mid-1950s, penicillin resistance was so
prevalent that the antibiotic was no longer effective for treat-
ment of infections. Methicillin-resistant S. aureus (MRSA)ogy.was reported in the early 1960s and then ultimately spread
worldwide over the next several decades. MRSA is now
endemic in health care facilities in virtually all industrialized
countries, although recent data indicate a decrease in
the number of invasive MRSA infections in US health
care facilities.8 Community-associated MRSA (CA-MRSA)
appeared inexplicably in the 1990s and is currently a major
problem in many countries worldwide, including the United
States.8,9 Unlike health careeassociated MRSA infections,
which occur in individuals with predisposing risk factors,
CA-MRSA typically causes disease in otherwise healthy in-
dividuals. Although resistance to b-lactam antibiotics is
arguably the greatest problem for treatment of S. aureus in-
fections, the pathogen can develop resistance to multiple
antibiotics beyond b-lactams, including vancomycin, an
important therapeutic agent for severe MRSA infections.9
Taking these attributes collectively, it is not surprising that
there is a high prevalence of S. aureus infections globally or
Figure 1 Staphylococcus aureus skin abscesses. A: Formation of a S. aureus skin abscess. B: Representative histopathological section of a typical rabbit
skin abscess at day 14 after infection. C: Increased magniﬁcation of the boxed area shown in B. D and E: Gram stains of histological sections of a rabbit
abscess. Arrows in D indicate S. aureus. The dark area is a colony of S. aureus. Arrows in E indicate S. aureus associated with leukocytes within the abscess.
These studies conformed to the guidelines set forth by the NIH and were approved by the Institutional Animal Care and Use Committee at Rocky Mountain
Laboratories, National Institute of Allergy and Infectious Diseases (Hamilton, Montana). PBS, phosphate-buffered saline; PMN, polymorphonuclear
leukocyte.
S. aureus Abscessesthat it remains a leading cause of pathogen-associated
morbidity and mortality in the United States.6,8,10,11
Although S. aureus causes a wide range of diseases and
syndromes, including bacteremia, pneumonia, cellulitis, and
osteomyelitis, most community-associated infections in theThe American Journal of Pathology - ajp.amjpathol.orgUnited States are those that affect skin and soft tissues.9,11,12
Of all military personnel, 4% to 6% ultimately acquire a skin
and soft tissue infection (SSTI), and 91% of these infections
are caused by S. aureus (70% are MRSA).10 A CA-MRSA
strain known as pulsed-ﬁeld type USA300 (referred1519
Kobayashi et alto herein as USA300) was the most frequently recovered
bacterial isolate from community-associated SSTIs in the
early-to-mid 2000s.3,13 This particular S. aureus strain
gained additional notoriety after it caused skin abscesses in
several US professional football players.14 USA300 has
remained the most frequent organism recovered from in-
dividuals reporting to hospital emergency departments for
purulent SSTIs,11 with infections classiﬁed as abscesses in
85% of these cases.11 Many SSTIs are relatively minor and
self-limiting, but complicated SSTIs can be life threatening.
There are several deﬁning features or clinical manifestations
of complicated S. aureus SSTIs, and these often include
formation of large abscesses.15
Herein, we review our current knowledge of the patho-
genesis of S. aureus abscesses, with emphasis on the
involvement of polymorphonuclear leukocytes (PMNs; or
neutrophils) and selected bacterial molecules.S. aureus SSTIs
The skin is an essential ﬁrst line of defense against invading
bacterial pathogens, including those present in the external
environment and opportunistic skin microbes. At the most
basic level, the skin serves as a physical barrier to prevent
entry of bacteria into deeper layers of tissue and/or dissem-
ination to internal organ systems. Keratinocytes form this
important physical barrier. Traumatic breech of the skin
enables entry of pathogenic microorganisms into the under-
lying tissue and initiates a complex cellular response that
includes mobilization of immune cells to the site of infection
(Figure 1A). The clinical presentation of bacterial SSTIs can
vary from superﬁcial to highly invasive and/or disseminated
disease. The importance of S. aureus in SSTIs has long been
appreciated since Alexander Ogston ﬁrst unveiled the role of
the pathogen in the etiology of the pyogenic abscess in the
late 19th century.16 Although a diversity of bacteria are
currently implicated in SSTIs, S. aureus is overwhelmingly
the most prominent cause of infection (eg, a recent study of a
large US health care delivery system found approximately
80% of SSTIs to be associated with S. aureus),17 with the
most common clinical presentation being abscess and
cellulitis (63%).
In addition to SSTIs, pyogenic bacterial abscesses can
form in deeper tissues, such as underlying muscle, and
bacteria can disseminate to form abscesses at distal sites and
affect virtually any internal organ system. The overall
structure of S. aureus abscesses is consistent regardless of
anatomical location, based, at least in part, on lesion histo-
pathology from experimental animal models of infection
(eg, rabbit SSTIs18 and murine skin,19 kidney,20 and
brain).21 Similarities aside, it is unclear if there are varia-
tions in organ-speciﬁc immune response and/or bacterial
response that may govern the process of abscess formation,
depending on anatomical location. Staphylococcus aureus
kidney abscesses in mice have features not found in1520S. aureus skin abscesses in rabbits. For example, Cheng
et al20 found a large mass of replicating S. aureus at the
center of the kidney abscess that was surrounded by an
eosinophilic pseudocapsuleda feature not observed in
rabbit skin abscesses.18 Inasmuch as S. aureus can produce
molecules that promote abscess formation (see below), it is
possible there is species and tissue speciﬁcity conferred by
these molecules.
The pyogenic abscess begins as a localized host acute
inﬂammatory response to bacterial infection. In addition to
serving as a physical barrier to protect against microbes,
keratinocytes possess pattern recognition receptors that
detect invading microbes and, in turn, signal the proin-
ﬂammatory response.22 These host cells also produce
antimicrobial peptides that have direct activity against S.
aureus.23,24 As an abscess forms, it acquires several char-
acteristic features. The center of the abscess contains an
acute inﬂammatory exudate composed of many viable and
necrotic PMNs, tissue debris, ﬁbrin, and live bacteria
(Figure 1).25 Maturation of the abscess is accompanied by
ﬁbroblastic proliferation and tissue repair at the abscess
margin and formation of a ﬁbrous capsule at the periphery
(Figure 1). SSTIs that present as bacterial abscesses form in
the dermis, epidermis, or subcutaneous tissue and are often
accompanied by cellulitis. Abscess formation is a mecha-
nism used by the host to contain and ultimately eliminate
the pathogen. Indeed, some SSTIs resolve spontaneously in
the absence of treatment. Notably, PMNs play a prominent
role in the formation and resolution of abscesses.
Circulating PMNs are elicited from the vasculature to the
infection site in response to tissue damage,26 host proin-
ﬂammatory molecules, and signals imparted directly by
bacteria.27 For example, S. aureus induces expression of
many host proinﬂammatory factors in vitro or during
experimental infection in mice, including IL-1a,28 IL-1b,29
IL-6,30 IL-8,31 IL-17,32 leukotriene B4,31 tumor necrosis
factor-a,33 CXCL1,34 and CXCL2.34 These factors are
known to promote PMN extravasation and recruitment to
infected tissues. Keratinocytes,35 T cells,34 PMNs,32 and
macrophages36 produce chemotactic factors that contribute
to the large inﬂux of neutrophils that occurs in response to S.
aureus SSTIs. In addition, experimental animal models
provide evidence that S. aureus SSTIs result in increased
numbers of PMNs in circulation,37 and myeloid progenitor cells
are recruited to infection sites where they undergo granulopoi-
esis.37,38 The accumulation and persistence of PMNs, followed
by necrotic cell lysis, contribute to the overall pathology of S.
aureus SSTIs.Innate Host Defense against S. aureus
Infectionsdthe Role of PMNs
PMNs are arguably the most important cellular defense
against invading bacteria, such as S. aureus. Indeed, ge-
netic disorders that negatively affect PMN functionajp.amjpathol.org - The American Journal of Pathology
Figure 2 Polymorphonuclear leukocyte phagocytosis and microbicidal
processes. Surface receptors for host opsonins, such as complement and anti-
body, promote ingestion of S. aureus, which, in turn, activates themicrobicidal
processes that operate in a bacteria-containing phagosome (the cytoplasmic
vacuole containing bacteria). The enzyme complex responsible for generation
of superoxidedNADPH oxidasedis depicted by the blue cluster of shapes on
the phagosomemembrane. CR, complement receptor; HOCl, hypochlorous acid;
MPO, myeloperoxidase; ROS, reactive oxygen species.
S. aureus Abscessestypically predispose individuals to severe (and frequent)
bacterial and fungal infections. For example, individuals
with chronic granulomatous disease, a genetic disorder
characterized by the inability of PMNs and other phago-
cytes to produce superoxide, often acquire severe and
recurrent S. aureus infections. These infections often
manifest as abscesses that can ultimately transform into
granulomas, which obstruct organ function and must be
surgically removed. Inasmuch as PMNs play a central role
in S. aureus abscess formation and the resolution of
infection, it is important to understand basic functions of
these prominent host cells.
Phagocytosis of Bacteria
Neutrophils are recruited rapidly to the site of infection and
remove invading microorganisms through a process known
as phagocytosis (Figure 2). Bacteria express a litany of
molecules on their surface, such as lipopolysaccharide,
lipoprotein, and lipoteichoic acid, and these pathogen-
associated molecular patterns interact with receptors on
the surface of neutrophils. In general, ligation of the
neutrophil pattern recognition receptors (eg, Toll-like re-
ceptors and CD14) activates signal transduction pathways
that ultimately contribute to bactericidal activity. PMN
phagocytosis is most efﬁciently promoted by opsonization
of bacteria with antibody and complement. Speciﬁc anti-
body binds to epitopes on the surface of bacteria and enables
the deposition of complement. Antibodies bound to the
bacterial surface are recognized by neutrophil receptorsThe American Journal of Pathology - ajp.amjpathol.orgspeciﬁc for the Fc region, including CD64 (FcgRI, IgG
receptor), CD32 (FcgRIIa, low-afﬁnity IgG receptor),
CD16 (FcgRIIIb, low-afﬁnity IgG receptor), CD89 (FcaR,
IgA receptor), and CD23 (FcεRI, IgE receptor). Bacteria
opsonized with complement are recognized by PMN sur-
face receptors, including ClqR, CD35, CD11b/CD18
(CR3), and CD11c/CD18 (CR4). Ingested bacteria are
sequestered within membrane-bound vacuoles called
phagosomes (Figure 2).
Killing of Bacteria
PMN phagocytosis is followed by the execution of bacte-
ricidal mechanisms, including the production of superoxide
radicals and other reactive oxygen species (ROS), and
enrichment of antimicrobial peptides, proteins, and degra-
dative enzymes in the phagosome (Figure 2). ROS are
generated by a multicomponent membrane-bound complex
known as the NADPH-dependent oxidase,39 which is
defective in individuals with chronic granulomatous dis-
ease. In resting neutrophils, components of the NADPH
oxidase are either cytosolic (p40phox, p47phox, p67phox,
and the GTPase Rac2) or located in membranes (ﬂavo-
cytochrome b558). NADPH oxidase assembly involves
translocation of the cytosolic protein components to the
plasma or phagosome membrane and their subsequent as-
sociation with ﬂavocytochrome b558, a transmembrane
heterodimer that serves as the nidus of the assembling
enzyme complex. After activation of the NADPH oxidase,
electrons are transported from cytosolic NADPH to molec-
ular oxygen, thereby generating superoxide anion.39 Multiple
oxygen metabolites, including hydrogen peroxide, superox-
ide anion, and hypochlorous acid, contribute to neutrophil
bactericidal activity.40
In addition to activation of PMN oxygen-dependent
bactericidal mechanisms, phagocytosis triggers degranula-
tion, which involves fusion of cytoplasmic granules with the
phagosome membrane (Figure 2).41,42 Peroxidase-negative
granules, including secretory vesicles, gelatinase granules,
and speciﬁc granules, are a reservoir of functionally
important membrane proteins, such as CR3, formyl peptide
receptor, ﬂavocytochrome b558, and b2-integrins.
40,43
Peroxidase-positive granules (primary/azurophilic gran-
ules) contain the bulk of oxygen-independent antimicrobial
agents of neutrophils, including a-defensins, cathepsins,
proteinase-3, elastase, azurocidin, lysozyme, and bacteri-
cidal permeabilityeincreasing protein.43 Thus, fusion of
azurophilic granules with phagosomes enriches these
microbe-containing vacuoles with a relatively large
repertoire of antimicrobial agents. PMN antimicrobial ac-
tivity, composed of ROS and a broad range of antimicro-
bial peptides and enzymes, is sufﬁcient to kill most
invading bacteria. Notwithstanding, bacterial pathogens,
such as S. aureus, have the ability to evade the host innate
immune response to promote disease. Indeed, there are
numerous S. aureus molecules that can contribute to1521
Figure 3 Staphylococcus aureus virulence molecules. Staphylococcus aureus can produce multiple types of molecules that contribute to virulence and
pathogenesis. Many of these molecules have been linked to the pathogenesis of abscesses (red text). AhpCF, alkyl hydroperoxide reductase subunits C and F;
Aur, aureolysin; BsaA, glutathione peroxidase; CHIPS, chemotaxis inhibitory protein of staphylococcus; Clf, clumping factor; Cna, collagen adhesin; Coa,
coagulase; CPS, capsule; Eap, extracellular adherence protein; Efb, extracellular ﬁbrinogen binding protein; FLIPr, formyl peptide receptor-like 1 inhibitory
protein; fMLP, N-formyl-methionyl-leucyl-phenylalanine; FnBPAB, ﬁbronectin binding protein A and B; Hla, a-hemolysin; HlgABC, gamma-hemolysin subunits
A, B, and C; IcaADBCR, intercellular adhesin subunits A, D, B, C, and R; Isd, iron-regulated surface determinant; KatA, catalase; LTA, lipoteichoic acid; Luk,
leukocidin; MprF, multiple peptide resistance factor; OatA, O-acetyltransferase A; PSM, phenol-soluble modulin; PVL, Panton-Valentine leukocidin; ROS,
reactive oxygen species; Sak, staphylokinase; Sbi, staphylococcal IgG-binding protein; SCIN, staphylococcal complement inhibitor; SdrCDE, Ser-Asp rich
ﬁbrinogen/bone sialoprotein-binding protein subunits C, D, and E; SE, staphylococcal enterotoxin; SOD, superoxide dismutase; Spa, staphylococcal protein A;
SSL, staphylococcal superantigen-like protein; SXN, staphyloxanthin; TrxAB, thioredoxin (TrxA) and thioredoxin reductase (TrxB); vWbp, von Willebrand factor
binding protein; WTA, wall techoic acid.
Kobayashi et aldestruction of PMNs, and these molecules are discussed
below in more detail.
Molecules Produced by S. aureus that
Affect/Alter PMN Function and Viability
S. aureus Immune Evasion Molecules
Staphylococcus aureus produces an array of potential viru-
lence factors that play an important role on every level of
host-pathogen interactions, including immune evasion mole-
cules that allow bacteria to circumvent host innate and
adaptive immunity. A multitude of these virulence factors
protects S. aureus from bactericidal activity of PMNs or
directly alters neutrophil function.44 These molecules can be
categorized according to their functions, and include those
that do the following: i) affect PMN recruitment, ii) moderate
the effects of phagocyte microbicides, iii) alter phagocytosis,
and iv) cause host cell lysis (cytolytic toxins) (Figure 3).
As an example, S. aureus secretes short N-formylated
peptides, which are produced during protein biosynthesis or
released during bacterial cytolysis. These peptides generate a
chemotactic gradient for PMNs.45 N-formylated peptides,
along with other bacteria-derived molecules, also signal resi-
dent host cells to produce proinﬂammatory molecules (che-
moattractants) that signal PMN recruitment. The battle
between S. aureus and PMNs begins early during infection,1522during which time, for example, secreted staphylococcal
superantigen-like protein-5 andprotein-11 obstruct interaction
of PSGL-1 on the PMN surface and P-selectin on the endo-
thelial lining, thereby blocking PMN rolling in the vessel.46,47
Extracellular adherence protein hinders association of Mac-1
and intercellular adhesion molecule-1 or binding of lympho-
cyte function-associated antigen-1 to intercellular adhesion
molecule-1, which negatively affects PMN adhesion and
diapedesis through the endothelium of the blood vessel.48
After extravasation, PMNs migrate toward infection sites on
the basis of an increasing gradient of chemoattractants, which
involve, in part, the formyl peptide receptor, C5a receptor, and
formyl peptide receptor like-1. To counter this process, the
chemotaxis inhibitory protein of staphylococcus and staphy-
lococcal complement inhibitor are directed to inhibit chemo-
taxis dependent on C5a and formyl peptide receptor, and
formyl peptide receptor-like 1 inhibitory protein impedes
formyl peptide receptor like-1edependent migration of
PMNs.49e52 At the site of S. aureus infection, PMNs
encounter secreted cytolytic toxins that can permeabilize host
cell plasma membranes and/or cause rapid cytolysis and must
overcome the effects of molecules that potentially inhibit
bacterial uptake. Among these antiphagocytic molecules are
protein A, which binds the Fc region of IgG (thereby blocking
opsonization with speciﬁc antibody), clumping factor A, and
extracellular ﬁbrinogen binding protein, which blocks
phagocytosis by depositing ﬁbrinogen on the bacterialajp.amjpathol.org - The American Journal of Pathology
S. aureus Abscessessurface.53e55 Despite these obstacles, S. aureus is readily
engulfed by PMNsdespecially by those that are adherent.
Bacterial pathogens have also evolved mechanisms to
protect against oxygen-dependent and oxygen-independent
killing by human PMNs (Figure 3). For example, S. aureus
uses alkyl hydroperoxide reductase, catalase, and superoxide
dismutase to protect againstROS.56Moreover, staphylococcal
golden pigment or staphyloxanthin functions as an antioxidant
and is additional protection against ROS.57 Staphylococcus
aureus has multiple, redundant molecules/systems that pro-
mote resistance to antimicrobial peptides, and such resistance
typically involves modiﬁcation of the cell wall.44
Thus, given the prominent role played by PMNs in host
defense against S. aureus infections, and considering the
pathogen has many molecules that can potentially contribute
to evasion of neutrophil function, it is not surprising that
PMNs play a major role in the formation of abscesses.
Lysis of PMNs and the Role of S. aureus Secreted Toxins
To maintain proper homeostasis, the host immune system is
subject to constant turnover of cells, including neutrophils.
Typically, aging PMNs undergo apoptosis and are removed
by macrophages in a process known as efferocytosis.58
However, bacteria such as S. aureus have the ability to alter
and/or circumvent this process and cause PMN lysis.59
Because PMNs contain numerous cytotoxic and proin-
ﬂammatory molecules, uncontrolled lysis can have pivotal
consequences to host health and additionally can promote
dissemination of bacteria previously contained within phag-
osomes. Recent studies revealed that after PMN engulfment,
S. aureus is able to divert PMNs from conventional apoptotic
pathways and cause subsequent lysis of these host cells by
means of a process termed programmed necrosis.60 In vitro
studies have shown that within 3 to 4 hours after phagocytosis
of S. aureus, neutrophils initiate morphological changes, such
as blebbing, increase exposure of phosphatidylserine on the
surface of the cell, and nuclear condensation, which are
hallmarks of PMN apoptosis. Although the initial steps of
programmed necrosis are similar to apoptosis, S. aureusein-
duced programmed necrosis is a receptor-interacting protein
1edependent process that does not result in activation of
caspases 2, 3, 8, and 9.60 Moreover, PMN phagocytosis of S.
aureus is accompanied by increased expression of CD47 (a
don’t eat me signal), a molecule that has been shown to prevent
efferocytosis of apoptotic PMNs by macrophages.60 Notably,
bacterial burden plays an essential role in directing PMNs
toward programmed necrosis. Inasmuch as a relatively high
bacteria/PMN ratio (10:1) is sufﬁcient to induce the process, a
low bacterial burden (1:1) requires additional caspase inhibi-
tion. Furthermore, engulfment of S. aureus by PMNs alters
macrophage production of cytokines, such as IL-6, IL-8, or
tumor necrosis factor-a, and lowers secretion of IL-1b, which
is an essential cytokine in subcutaneous infections.29,60,61
In addition to triggering programmed necrosis, S. aureus
secretes virulence factors that promote direct lysis of neutrophilsThe American Journal of Pathology - ajp.amjpathol.org(Figure 3). Among them are leukotoxins, such as Panton-
Valentine leukocidin, leukocidin GH, or leukocidin DE,
and a-type phenol-soluble modulins, g-hemolysin, and d-
toxin.62e72 Permeabilization of the cell membrane by Panton-
Valentine leukocidin or leukocidin GH can cause neutrophil
lysis that results in the formation of structures called neutro-
phil extracellular traps, which are web-like structures of nu-
clear DNA towhich histones and other cationic molecules are
bound non-speciﬁcally.73e75 Whether these structures play a
direct role in the formation of abscesses is not clear, although
there is no question that abscesses contain a bolus of lysed
PMNs and PMN debris, which includes extracellular DNA.Hla and Dermonecrosis
a-Hemolysin (Hla; a-toxin) is one of the earliest studied
staphylococcal virulence factors.76,77 This pore-forming cyto-
toxin is freely secreted by S. aureus as a water-soluble mono-
mer, and then binds the surface of target cells, forming a
heptameric transmembrane pore.78 Formation of functional
pores generates ion imbalance, including efﬂux of potassium
cations and ATP or inﬂux of calcium ions, and ultimately leads
to cell death. Hla targets many different cell types, including
epithelial and endothelial cells, blood cells, and platelets.79
Hla plays a crucial role in the pathogenesis of S. aureus
SSTIs and, in particular, promotes dermonecrosis in animal
infection models. Functional inactivation of the gene encod-
ing Hla by mutagenesis or deletion, or passive or active
immunization against this toxin, signiﬁcantly reduces size of
abscesses and virtually eliminates dermonecrosis in animal
infection models.18,19,80e82 The relatively recent discovery of
an Hla receptorda disintegrin and metalloprotease 10dwas
a major advance for our understanding of the role played by
Hla during SSTIs.83 By activating a disintegrin and metal-
loprotease 10, Hla contributes to proteolysis of E-cadherin,
which leads to the disruption of the adherens junction in the
epithelial layer, thereby prompting potential remodeling of
the epithelial layer and consequently pathogen dissemina-
tion.83,84 In a similar manner, Hla contributes to the breach of
blood vessel endothelium integrity by causing proteolysis of
the extracellular domain of vascular endothelial cadherin.85
The toxin also promotes a vigorous host inﬂammatory
response, and this response has been linked to increased
morbidity and mortality in animal infection models (eg, in S.
aureus pneumonia).86 Hla also acts directly or indirectly with
intracellular host sensor molecules, notably, members of the
nucleotide-binding domain leucine-rich repeat containing
(NLR) family, such as NLRC2 and NLRP3.87e89 Activation
of the NLRP3 inﬂammasome by Hla and costimulation of
NLRC2 by Hla and muramyl dipeptide trigger downstream
activation of caspase 1, which subsequently leads to activa-
tion of the potent proinﬂammatory cytokine IL-1b that
largely contributes to PMN inﬂux to the site of infection.87,88
The ability of Hla to cause host cell cytolysis (and thus
destabilize the dermis) and elicit neutrophil recruitment1523
Kobayashi et allikely plays a central role in the pathogenesis of SSTIs. More
notably, Hla can promote dermonecrosis in animal skin
infection models, a more severe manifestation of SSTIs.
Whether this virulence attribute of Hla is recapitulated in
human SSTIs remains unknown, but the toxin is potentially a
target for therapeutics designed to moderate the severity of
disease. Key features of mature abscesses in experimental
animal models and those of humans have many similar at-
tributes, and thus the experimental abscesses in animals seem
to be a reasonable approximation of S. aureus skin abscesses
in humans. However, there are clear differences between
experimental S. aureus abscesses in animals and human S.
aureus abscesses. These differences include those in the
innate immune systems of experimental animals and humans;
for example, there are known differences in the ability of
leukocidins, such as Panton-Valentine leukocidin, to cause
cytolysis of rodent and human PMNs.90
Coagulases
Although the contribution of Hla to S. aureus SSTIs is clear
in animal infection models, there is little known about the
contribution of additional staphylococcal factors to abscess
formation and development. Notwithstanding, several recent
studies provide evidence that S. aureus coagulase (Coa) and
von Willebrand factor binding protein (vWbp) facilitate
abscess formation in a mouse model of disseminated
infection.91e93 Coa and vWbp are perhaps best known for
their ability to alter host defense by promoting coagulation
and altering normal hemostasis, and thus contribute to S.
aureus pathogenesis.91,94 Both Coa and vWbp activate
prothrombin in a non-proteolytic manner, which diverts
prothrombin activation away from host regulation.95,96
Furthermore, the C-terminal domain of Coa binds ﬁbrin-
ogen and subsequently enables proteolytic conversion of
ﬁbrinogen to ﬁbrin, and the deposition of ﬁbrin. Coagulase
and high levels of vWbp accumulate at the abscess pe-
ripheries, and these molecules likely contribute to abscess
development via formation of a pseudocapsule (also called
ﬁbrous capsule) and microcolony-associated meshwork.97
These structures generate a mechanical barrier that hinders
the recognition and phagocytosis of bacteria by host neu-
trophils and other immune cells.98 Single Coa or vWbp
deletion mutants alter bacterial survival and/or decrease
abscess formation, but the greatest decrease in abscess for-
mation occurs with coa/vwbp double deletion mutant strains
in animal infection models. This phenomenon is likely
correlated with functional redundancy of Coa and vWbp
during prothrombin activation and ﬁbrin deposition.93,97
The importance of Coa and vWbp in the formation of
S. aureus abscesses is best illustrated by recent vaccine
studies, in which active and passive immunization with anti-
bodies against Coa and vWbp signiﬁcantly reduced number of
lesions in a murine kidney abscess model.93,97 Whether such
an approach would be successful in treatment or prevention of
severe/complicated SSTIs remains unclear.1524Treatment and Future Perspective
Staphylococcus aureus is a human commensal microbe and
has been a cause of infections throughout recorded history.
There is no question that it will continue to be a signiﬁcant
cause of human infections. Many of the infections caused by
S. aureus are nonsevere SSTIs that are self-limiting or
resolve without therapeutic intervention. However, severe or
complicated SSTIs require some type of therapy or treat-
ment. Indeed, skin infections often led to invasive disease or
death before the antibiotic era.65
The Infectious Diseases Society of America has set forth
speciﬁc guidelines for treatment of S. aureus SSTIs.99
Incision and drainage alone is the recommended treat-
ment for cutaneous abscesses, whereas antibiotics are
recommended only for abscesses associated with severe
and/or disseminated disease or those that fail to respond to
incision and drainage.100 That said, outpatients with minor
abscesses can be treated with empirical antibiotic therapy
that is effective against CA-MRSA.100 Such antibiotics
include trimethoprim-sulfamethoxazole, clindamycin, and
doxycycline or minocycline.99,100 By comparison, vanco-
mycin, linezolid, daptomycin, televancin, and clindamycin
are among the antibiotics recommended for hospitalized
patients with complicated SSTIs, which include major
abscesses.99
Given the ability of S. aureus to develop resistance to
antibiotics rapidly, it is worthwhile to consider alternative
therapies fordor prophylactic measures to preventdsevere
S. aureus disease. A potential therapeutic and/or prophy-
lactic approach is the use of active or passive vaccination
against S. aureus molecules known to promote severe
SSTIs. There has been signiﬁcant effort put forth in recent
years to develop a vaccine designed to protect against S.
aureus infection, but these vaccines have failed in human
clinical trials.101 One confounding issue is our lack of
knowledge about the factors (both host and microbe) that
contribute to protective immunity against S. aureus in-
fections. Recently, Fritz et al102 reported that anti-Hla
antibody titers correlate with protection against subsequent
S. aureus infection, albeit SSTIs elicit a limited protective
immune response. Consistent with those ﬁndings, work in
mouse infection models has demonstrated that antibodies
directed against Hla, Coa, and vWbp protect against severe
S. aureus skin disease.19,93 Sampedro et al103 took these
models one step further by testing the ability of anti-Hla
approaches, which include direct toxin neutralization or
receptor blocking, to moderate or prevent recurrent S.
aureus SSTIs in a mouse model.
Collectively, these studies suggest that it should be
possible to use a vaccine or similar (eg, receptor blocking)
approach for treatment, moderation, or prevention of severe
SSTIs. Although signiﬁcant progress has been made (eg, use
of incision and drainage as a treatment approach), more
work is needed in this general area to develop therapies that
are not dependent on antibiotics.ajp.amjpathol.org - The American Journal of Pathology
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